Schwab Charles Investment Management Inc. Sells 10,583 Shares of Masimo (MASI)

Schwab Charles Investment Management Inc. trimmed its holdings in shares of Masimo (NASDAQ:MASI) by 2.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 361,361 shares of the medical equipment provider’s stock after selling 10,583 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.70% of Masimo worth $31,782,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the stock. Intrust Bank NA increased its position in Masimo by 15.5% during the first quarter. Intrust Bank NA now owns 4,490 shares of the medical equipment provider’s stock worth $395,000 after acquiring an additional 603 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in Masimo by 7.4% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 10,368 shares of the medical equipment provider’s stock worth $879,000 after acquiring an additional 718 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Masimo by 39.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,820 shares of the medical equipment provider’s stock worth $239,000 after acquiring an additional 802 shares during the period. Brown Capital Management LLC increased its position in Masimo by 0.8% during the fourth quarter. Brown Capital Management LLC now owns 98,506 shares of the medical equipment provider’s stock worth $8,353,000 after acquiring an additional 819 shares during the period. Finally, Eagle Asset Management Inc. increased its position in Masimo by 2.8% during the fourth quarter. Eagle Asset Management Inc. now owns 33,704 shares of the medical equipment provider’s stock worth $2,858,000 after acquiring an additional 932 shares during the period. 82.92% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider Jon Coleman sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 3rd. The shares were sold at an average price of $93.75, for a total value of $4,687,500.00. Following the sale, the insider now directly owns 34,201 shares in the company, valued at approximately $3,206,343.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Yongsam Lee sold 4,100 shares of the firm’s stock in a transaction that occurred on Tuesday, April 24th. The shares were sold at an average price of $90.13, for a total transaction of $369,533.00. Following the completion of the sale, the executive vice president now owns 72,200 shares in the company, valued at $6,507,386. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 122,303 shares of company stock worth $11,148,690. 12.60% of the stock is currently owned by corporate insiders.

Shares of Masimo opened at $99.12 on Friday, Marketbeat Ratings reports. The stock has a market cap of $5.13 billion, a price-to-earnings ratio of 40.46, a PEG ratio of 2.37 and a beta of 0.95. Masimo has a 12-month low of $80.69 and a 12-month high of $100.00.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.06. The firm had revenue of $212.90 million for the quarter, compared to the consensus estimate of $205.65 million. Masimo had a net margin of 15.99% and a return on equity of 23.14%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.57 earnings per share. equities analysts predict that Masimo will post 2.88 EPS for the current fiscal year.

MASI has been the topic of a number of recent research reports. Barclays assumed coverage on shares of Masimo in a research report on Friday, March 9th. They set an “overweight” rating and a $97.00 price target on the stock. Zacks Investment Research upgraded shares of Masimo from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research note on Tuesday, March 6th. BidaskClub upgraded shares of Masimo from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Piper Jaffray Companies reiterated a “hold” rating and set a $91.00 price objective on shares of Masimo in a research note on Thursday, March 1st. Finally, ValuEngine upgraded shares of Masimo from a “hold” rating to a “buy” rating in a research note on Monday, May 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Masimo currently has a consensus rating of “Buy” and a consensus target price of $101.17.

Masimo Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply